This webinar discusses how next-generation sequencing (NGS) can help clinical research labs and pathologists save time, money, and samples compared to single-analyte oncology research assays.
Recent studies estimate that almost 73 percent of cancer treatments in the pipeline may need a genomic biomarker in the next few years. As the list of genomic biomarkers relevant to clinical oncology keeps growing, the ability to detect mutations across hundreds of targets in a rapid, cost-efficient fashion helps pathology research laboratories conserve samples by reducing the need for sequential, single-analyte assays. NGS panels have revolutionized the field of cancer genomics by enabling pathologists and clinical researchers to analyze mutations across multiple genes, in a single assay.
For clinical research or pathology laboratories that are considering adopting NGS in house, it’s important that the chosen solutions are compatible with challenging sample types (such as fine needle aspirates and formalin-fixed, paraffin-embedded samples), have an automated wet-lab workflow, and offer plug-and-play bioinformatics capabilities.
During this webinar, Dr. Navid Sadri of the University Hospitals Cleveland Medical Center provides an overview of why his pathology lab adopted NGS and how it is being implemented for clinical research. He provides some examples of how NGS helped identify different mutation types and provides relevant results with limited sample input and a rapid turnaround time.
Thereafter, Dr. Jody McIntyre of Thermo Fisher Scientific shows how Oncomine KnowledgeBase Reporter can help pathologists and clinical researchers link cancer variants to labels, guidelines and clinical trials, and generate an easy-to-interpret report in a few simple steps.